These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25796091)

  • 21. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N; Zhang Q; Fang S; Han X; Wang Z
    Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment.
    Zhao YF; Wang CR; Wu YM; Ma SL; Ji Y; Lu YJ
    Biomed Pharmacother; 2011 Jun; 65(3):151-6. PubMed ID: 21616632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.
    Xu F; Tian Y; Huang Y; Zhang LL; Guo ZZ; Huang JJ; Lin TY
    Chin J Cancer; 2011 Oct; 30(10):701-11. PubMed ID: 21959047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiosensitization of Non-Small Cell Lung Cancer Cells by Inhibition of TGF-β1 Signaling With SB431542 Is Dependent on p53 Status.
    Zhao Y; Wang L; Huang Q; Jiang Y; Wang J; Zhang L; Tian Y; Yang H
    Oncol Res; 2016; 24(1):1-7. PubMed ID: 27178816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
    Rho JK; Choi YJ; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
    Cancer Res; 2007 Feb; 67(3):1163-9. PubMed ID: 17283151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
    Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
    Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
    Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
    Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells.
    Yin J; Zhang H; Wu X; Zhang Y; Li J; Shen J; Zhao Y; Xiao Z; Lu L; Huang C; Zhang Z; Du F; Wu Y; Kaboli PJ; Cho CH; Yuan D; Li M
    Int J Mol Med; 2020 Jun; 45(6):1783-1792. PubMed ID: 32236608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
    Jänne PA; Taffaro ML; Salgia R; Johnson BE
    Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracytoplasmic epidermal growth factor receptor shows poor response to the cetuximab antitumor effect in irradiated non-small cell lung cancer cell lines.
    Ryu SH; Lee SW; Yang YJ; Song SY; Kim JH; Choi EK; Ahn SD
    Lung Cancer; 2012 Sep; 77(3):482-7. PubMed ID: 22704525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proliferation arrest in G1 phase of a non-small cell lung cancer cell line (NSCLC-N6) treated by an original compound methyl-4-methoxy-3-(3-methyl-2-butanoyl) benzoate (VT1) independently of the p53/p21 cascade.
    Jacquot C; Moreau D; Tomasoni C; Juge M; Coiffard L; Roussis V; Roussakis C
    Int J Oncol; 2003 Aug; 23(2):495-501. PubMed ID: 12851701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
    Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pifithrin-μ is efficacious against non-small cell lung cancer via inhibition of heat shock protein 70.
    Zhou Y; Ma J; Zhang J; He L; Gong J; Long C
    Oncol Rep; 2017 Jan; 37(1):313-322. PubMed ID: 28004121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
    J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells.
    Kol A; Terwisscha van Scheltinga A; Pool M; Gerdes C; de Vries E; de Jong S
    Oncotarget; 2017 Jul; 8(28):45432-45446. PubMed ID: 28467975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
    Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
    Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
    Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
    Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
    Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.